SMTI — Sanara MedTech Inc.

Sanara MedTech (SMTI) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Revenue: Achieved $26.3 million, a 22% year-over-year increase, primarily driven by a 24% increase in soft tissue repair product sales, totaling $23.4 million.
• Gross Profit: Increased by $4.8 million (24%) to $24.5 million, with gross margins rising to 93%.
• Operating Income: Rose by $2.2 million (278%) to $2.9 million.
• Net Income: Reported at $800,000 ($0.09 per diluted share), compared to a net loss of $200,000 in the previous year.
• Adjusted EBITDA: Increased by $2.3 million to $4.9 million.
• Cash Position: As of September 30, 2025, cash was $14.9 million, with long-term debt at $45.1 million.

2. Strategic Updates and Business Highlights:

• Leadership Change: Seth Yon was appointed President and CEO on September 15, 2025, emphasizing a focus on core surgical products (CellerateRX and BIASURGE).
• Discontinuation of Tissue Health Plus (THP): After evaluating strategic alternatives, management decided to cease THP operations to enhance operational efficiency and focus resources on the surgical business. Expected cash investment related to THP is projected at $5.5 million to $6.5 million for the second half of 2025.
• Commercial Strategy: The company expanded its distributor network from over 300 to more than 400 and increased healthcare facility sales from 1,200 to 1,400 over the past year.
• Clinical Evidence: Two studies published in peer-reviewed journals highlighted the effectiveness of CellerateRX in complex surgical procedures.

3. Forward Guidance and Outlook:

• Q4 2025 Expectations: Revenue growth is anticipated in the high single digits to low teens year-over-year, excluding a one-time benefit from the previous year.
• Long-term Growth: The company aims to leverage its strengths in the surgical market, focusing on expanding surgeon usage within existing facilities and enhancing operational efficiency.

4. Bad News, Challenges, or Points of Concern:

• THP Discontinuation: The decision to cease THP operations was seen as a setback, reflecting challenges in finding a strategic partner and the need for significant investment to bring THP to market.
• Operating Expenses: Operating expenses increased by 14% to $21.5 million, driven by higher selling, general, and administrative costs, which may impact profitability if not managed effectively.
• Market Dynamics: The company faces competitive pressures and must continue to innovate and expand its market presence to sustain growth.

5. Notable Q&A Insights:

• Sales Penetration: Management emphasized ongoing efforts to penetrate existing healthcare facilities and expand into new specialties, supported by strong clinical evidence and training for distributor representatives.
• Operating Profitability: There is potential for operating leverage and margin expansion as the company continues to grow with a flat headcount in sales.
• Future Growth Expectations: Management expressed confidence in maintaining strong performance despite a deceleration in growth rates compared to previous quarters, highlighting the significant opportunities within their existing customer base.

Overall, Sanara MedTech reported solid financial performance in Q3 2025, with strategic realignments aimed at enhancing focus on its core surgical business, despite challenges related to the discontinuation of THP. The company remains optimistic about future growth prospects.